Ajanta Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ajanta Pharma Limited Pharmaceutical Export Portfolio Dataset — 37 Products, $116.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ajanta Pharma Limited — Pharmaceutical Exporter Profile (2026) | 37 Products, $116.1M Trade | TransData Nexus

Ajanta Pharma Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $116.1M Total Trade · DGFT Verified

Ajanta Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $116.1M across 37 products in 17 therapeutic categories. Based on 3,643 verified export shipments from Indian Customs (DGFT) records, Ajanta Pharma Limited is the #1 Indian exporter in 5 products including Dapagliflozin, Febuxostat, Vildagliptin. Top exports include Artemether ($15.1M), Amlodipine ($12.4M), Clopidogrel ($7.0M).

Ajanta Pharma Limited — Export Portfolio & Destination Treemap

Ajanta Pharma Limited pharmaceutical export portfolio — 37 products across 17 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ajanta Pharma Limited? — Company Overview & Market Position

Ajanta Pharma Limited, established in 1973, is a specialty pharmaceutical company headquartered in Mumbai, India. The company specializes in the development, manufacturing, and marketing of branded generic formulations across various therapeutic areas, including cardiology, dermatology, ophthalmology, and pain management. Ajanta Pharma operates in over 30 countries, including the United States, Africa, Southeast Asia, and the Middle East.

As of March 2025, Ajanta Pharma reported a revenue of ₹5,555 crore (approximately $555.5 million USD), reflecting a 10.4% increase from the previous fiscal year. The company employs over 9,600 individuals globally. Ajanta Pharma is listed on the National Stock Exchange of India under the ticker symbol AJANTPHARM.

What Does Ajanta Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artemether$15.1M 2Amlodipine$12.4M

Product Portfolio — Top 30 by Export Value

Ajanta Pharma Limited exports 37 pharmaceutical products across 17 therapeutic categories. Market leader (#1 exporter) in 5 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artemether	Antimalarial & Antiparasitic	$15.1M	391	1.7%	7
2	Amlodipine	Cardiovascular	$12.4M	375	0.1%	9
3	Clopidogrel	Cardiovascular	$7.0M	140	2.8%	8
4	Rosuvastatin	Cardiovascular	$6.5M	155	1.4%	14
5	Montelukast	Respiratory	$6.4M	128	3.8%	3
6	Valsartan	Cardiovascular	$6.3M	170	3.2%	6
7	Azithromycin	Antibiotics	$5.8M	278	3.2%	8
8	Kit	Medical Devices & Diagnostics	$5.4M	339	1.2%	10
9	Dapagliflozin	Advanced Diabetes Medications	$5.2M	103	10.4%	1
10	Fenofibrate	Lipid & Metabolism	$4.7M	105	6.4%	6
11	Febuxostat	Lipid & Metabolism	$4.5M	89	9.1%	1
12	Clarithromycin	Antibiotics	$4.0M	109	4.1%	7
13	Losartan	Cardiovascular	$3.5M	69	1.1%	7
14	Cetirizine	Antihistamines & Allergy	$3.3M	66	1.9%	3
15	Cefixime	Advanced Antibiotics	$2.9M	63	1.7%	12
16	Vitamin	Nutritional Supplements	$2.4M	80	1.7%	9
17	Secnidazole	Advanced Antibiotics	$2.0M	90	6.7%	3
18	Vildagliptin	Advanced Diabetes Medications	$1.8M	92	18.0%	1
19	Pioglitazone	Diabetes & Endocrine	$1.8M	36	4.7%	5
20	Fluconazole	Antifungals	$1.5M	88	1.6%	13
21	Amikacin	Advanced Antibiotics	$1.4M	28	6.6%	3
22	Moxifloxacin	Advanced Antibiotics	$1.4M	112	4.2%	5
23	Voriconazole	Advanced Antifungals	$1.4M	27	4.3%	4
24	Captopril	Cardiovascular	$1.3M	60	10.5%	2
25	Levofloxacin	Antibiotics	$1.3M	81	1.8%	12
26	Aspirin	Analgesics & Antipyretics	$1.2M	28	3.3%	11
27	Glimepiride	Diabetes & Endocrine	$1.2M	41	1.5%	9
28	Ramipril	Cardiovascular	$937.2K	68	1.0%	15
29	Flucloxacillin	Advanced Antibiotics	$860.1K	76	2.2%	7
30	Atenolol	Cardiovascular	$850.0K	17	2.1%	11

Ajanta Pharma Limited exports 37 pharmaceutical products across 17 therapeutic categories with a total export value of $116.1M. The company is the #1 Indian exporter in 5 products: Dapagliflozin, Febuxostat, Vildagliptin. The top category is Cardiovascular (33.8% of portfolio), followed by Antimalarial & Antiparasitic (13.0%), reflecting a diversified portfolio where the top 5 products account for only 40.9% of total value.

Showing top 30 of 37 products. Contact us for complete data.

Ajanta Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ajanta Pharma operates seven state-of-the-art manufacturing facilities in India. Six of these facilities are dedicated to the production of finished pharmaceutical formulations, while one facility manufactures Active Pharmaceutical Ingredients (APIs) primarily for captive consumption. The company's manufacturing plants are located in Maharashtra, Gujarat, Assam, and Madhya Pradesh. Notably, the Paithan plant in Maharashtra and the Dahej plant in Gujarat have received approvals from stringent regulatory authorities, including the US FDA and the World Health Organization (WHO).

3Key Leadership

Ajanta Pharma's leadership team is headed by Managing Director Yogesh Mannalal Agrawal, who has been with the company since 2000. Rajesh Mannalal Agrawal serves as the Joint Managing Director and Director, having joined the company in 2013. Arvind K. Agrawal holds the position of Chief Financial Officer, overseeing the company's financial operations. Madhusudan Bhagwandas Agrawal serves as the Executive Vice Chairman of the Board, contributing to strategic decision-making processes.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ajanta Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

In the United States, Ajanta Pharma has established a significant presence in the generics market. As of December 30, 2025, the company has received 50 Abbreviated New Drug Application (ANDA) approvals, with 49 products commercialized. Ajanta Pharma plans to file 8-12 ANDAs annually, focusing on niche and complex products. The company's subsidiary, Ajanta Pharma USA Inc., markets these products, emphasizing supply chain reliability and flexibility to meet the unique needs of the US market.

In the European Union, Ajanta Pharma has obtained Good Manufacturing Practice (GMP) certifications for its manufacturing facilities, ensuring compliance with EU standards. The company has also received prequalification from the World Health Organization (WHO) for certain products, facilitating access to international markets.

2Emerging Markets

Ajanta Pharma has a strong foothold in emerging markets across Africa, Southeast Asia, Central Asia, and the Middle East. The company offers a diverse portfolio of branded generics, including antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management products. Ajanta Pharma's ability to identify market gaps and launch differentiated products has enabled it to establish leadership positions in several therapeutic areas within these regions.

Geographic Strategy

Ajanta Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Ajanta Pharma's manufacturing facilities, particularly those in Paithan, Maharashtra, and Dahej, Gujarat, are registered with the US Food and Drug Administration (FDA). The company has received multiple ANDA approvals for its generic products, with a significant number commercialized in the US market. Ajanta Pharma's commitment to quality and compliance is evident in its adherence to FDA regulations, ensuring the safety and efficacy of its products.

2WHO & EU GMP

Ajanta Pharma has achieved prequalification from the World Health Organization (WHO) for certain products, facilitating access to international markets. The company's manufacturing facilities have also received Good Manufacturing Practice (GMP) certifications from the European Union, ensuring compliance with EU standards. These certifications underscore Ajanta Pharma's commitment to maintaining high-quality manufacturing processes and meeting international regulatory requirements.

3CDSCO & Indian Regulatory

Ajanta Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ajanta Pharma operates in a competitive landscape with several key players in the generic pharmaceutical market. In the United States, the company faces competition from other generic manufacturers offering similar products. In emerging markets, Ajanta Pharma competes with both local and international pharmaceutical companies. The company's focus on niche and complex products, along with its strong regulatory compliance, provides a competitive edge in these markets. Ajanta Pharma's ability to identify and address unmet medical needs further differentiates it from competitors.

2Key Differentiators

Ajanta Pharma's key differentiators include its focus on niche and complex generic products, strong regulatory compliance, and ability to identify and address unmet medical needs. The company's diversified portfolio across various therapeutic areas and geographic regions allows it to mitigate risks and capitalize on growth opportunities. Ajanta Pharma's commitment to quality and innovation ensures that its products meet the highest standards, earning the trust of healthcare professionals and patients worldwide.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Ajanta Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ajanta Pharma has a robust track record in manufacturing and exporting pharmaceutical products. The company's facilities are approved by major regulatory authorities, including the US FDA and WHO, indicating a high level of reliability and compliance. Ajanta Pharma's consistent export volume and adherence to international standards reflect its commitment to quality and customer satisfaction. The company's strategic focus on niche and complex products further underscores its reliability as a supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Ajanta Pharma:

FDA Registration: Confirm that Ajanta Pharma's manufacturing facilities are registered with the US FDA. This can be verified through the FDA's Establishment Registration & Device Listing database.

WHO-GMP Certification: Ensure that the company's products are prequalified by the World Health Organization. Verification can be done by checking the WHO's list of prequalified medicinal products.

Frequently Asked Questions — Ajanta Pharma Limited

How many pharmaceutical products does Ajanta Pharma Limited export from India?

Ajanta Pharma Limited exports 37 pharmaceutical products across 17 therapeutic categories. The top exports are Artemether ($15.1M), Amlodipine ($12.4M), Clopidogrel ($7.0M), Rosuvastatin ($6.5M), Montelukast ($6.4M). Total export value is $116.1M.

What is Ajanta Pharma Limited's total pharmaceutical export value?

Ajanta Pharma Limited's total pharmaceutical export value is $116.1M, based on 3,643 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Ajanta Pharma Limited the #1 Indian exporter?

Ajanta Pharma Limited is the #1 Indian exporter in 5 products: Dapagliflozin (10.4% market share), Febuxostat (9.1% market share), Vildagliptin (18.0% market share).

What therapeutic categories does Ajanta Pharma Limited cover?

Ajanta Pharma Limited exports across 17 therapeutic categories. The largest are Cardiovascular (33.8%, 9 products), Antimalarial & Antiparasitic (13.0%, 1 products), Antibiotics (9.6%, 3 products).

Get Full Ajanta Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.